NASDAQ
107.52USD
+1.11 (+1.04%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
8.8B
P/E
—
EPS
—
Beta
1.96
52W range
36.65-130.05
Day range
104.80–108.12
Open
106.61
Prev close
106.41
Volume
459.2K
Avg volume
784.4K
Dividend
0.00
IPO
2020-08-21
https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-travere-therapeutics-inc-to-contact-law-firm-302834802.html · 7/27/2026-0.80
https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-kymera-therapeutics-inc-to-contact-law-firm-302834805.html · 7/27/2026-0.80
https://www.fool.com/coverage/filings/2026/07/12/kymera-s-ceo-sold-usd6-million-in-stock-after-a-170-run/ · 7/12/2026+0.80
https://seekingalpha.com/article/4919662-kymera-building-toward-a-defining-2h26-moment · 7/3/2026+0.90
https://www.zacks.com/stock/news/2935367/kymr-stock-gains-as-kt-485-starts-patient-dosing-in-hs-study?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2935367 · 6/10/2026+1.00
https://www.defenseworld.net/2026/04/19/vicor-nasdaqvicr-ceo-sells-9660500-00-in-stock.html · 4/19/2026-0.20
https://www.defenseworld.net/2026/04/19/insider-selling-kymera-therapeutics-nasdaqkymr-director-sells-374185-23-in-stock.html · 4/19/2026-0.20
https://www.zacks.com/stock/news/2898396/kymr-set-to-earn-milestone-payment-as-gild-secures-license-for-kt-200 · 4/10/2026+0.80
https://www.fool.com/coverage/filings/2026/03/19/nextech-trims-kymera-at-a-recent-high-think-foolishly-before-acting/ · 3/19/2026+0.00
https://www.fool.com/coverage/filings/2026/02/17/kymera-therapeutics-stock-up-120-in-1-year-as-fund-adds-usd3-million-more/ · 2/17/2026+0.80
https://www.marketbeat.com/originals/insider-buying-institutions-just-spent-100m-on-these-3-stocks/ · 1/1/2026+0.80
https://247wallst.com/investing/2025/12/17/share-offerings-prompt-huge-insider-buying-in-these-3-biotechs/ · 12/17/2025-0.20
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
